Overview

Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:
0

Participant gender:
All

Summary

The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.

Phase:

Phase 3

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

GE Healthcare

Treatments:

3-Iodobenzylguanidine

Criteria

Inclusion Criteria:

- Study subjects must be adults with an established diagnosis of heart failure (New York
Heart Association Class II or III) and reduced left ventricular ejection fraction
(LVEF) (≤ 35%) or be healthy volunteers without heart disease.

Exclusion Criteria:

- Healthy volunteers are not eligible if they have a history diabetes mellitus,
signs/symptoms of neurological disease (eg, Parkinson's Disease, multiple system
atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic
nervous system.

- Subjects with New York Heart Association Class I or IV heart failure are not eligible.